Exhibit 99.1
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for
QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022
Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter
2023
INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-line GIST Patients with Mutations in KIT Exon 11 and 17/18
Initiated with First Sites Open for Enrollment
DCC-3116 Combination
Escalation Cohorts with QINLOCK and with Encorafenib and Cetuximab Initiated with First Site Open for Enrollment; Combination Dose Escalation Cohorts with MEK and KRAS G12C Inhibitors Ongoing
WALTHAM, Mass. (BUSINESS WIRE)August 9, 2023Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on
discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
QINLOCK delivered record performance in the second quarter based on continued growth in the U.S. and around the world. Moving into a significant second
half of 2023, we are looking forward to the top-line results from the MOTION study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT), which has the potential to become our second approved
medicine, said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. Additionally, we have opened the first sites for INSIGHT, the pivotal Phase 3 study of QINLOCK versus sunitinib in second-line
gastrointestinal stromal tumor (GIST) patients with mutations in KIT exon 11 and 17 or 18 and for additional combination cohorts of our ULK inhibitor DCC-3116, one in combination with QINLOCK and another in
combination with encorafenib and cetuximab. We are on track to submit an Investigational New Drug application to the FDA for DCC-3084, a potential best-in-class pan-RAF inhibitor, in the fourth quarter.
Mr. Hoerter continued, We are proud of the significant progress across both our early-stage and late-stage programs that we have already
achieved in the first half of 2023. In addition to the INTRIGUE Phase 3 ctDNA analysis presented at the ASCO Plenary Session in the first quarter, we also presented eight poster presentations at AACR that showcased the depth and breadth of our
kinase switch-control research engine along with the nomination of our newest development candidate, DCC-3009, a potential
best-in-class pan-KIT inhibitor. At ASCO in June, we had one encore presentation of our INTRIGUE Phase 3 ctDNA analysis and three
poster presentations, including overall survival and long-term safety data from the INTRIGUE Phase 3 study of QINLOCK. Finally, on behalf of everyone at Deciphera, I would like to thank Dan Flynn for his dedication to Decipheras founding
vision of improving the lives of people with cancer, and for trailblazing the innovations that have made all these advancements possible. We are excited to build upon this foundation with Dash Dhanak as our new Chief Scientific Officer.
Second Quarter 2023 Highlights and Upcoming Milestones
QINLOCK® (ripretinib)